BioXcel Therapeutics (BTAI) Competitors $1.08 -0.05 (-4.42%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.28%) As of 05/19/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTAI vs. AIFC, COYA, EDSA, TTRX, and KLRSShould you buy BioXcel Therapeutics stock or one of its competitors? MarketBeat compares BioXcel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioXcel Therapeutics include ALT5 Sigma (AIFC), Coya Therapeutics (COYA), Edesa Biotech (EDSA), Turn Therapeutics (TTRX), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. BTAI vs. AIFCBTAI vs. COYABTAI vs. EDSABTAI vs. TTRXBTAI vs. KLRSHow does BioXcel Therapeutics compare to ALT5 Sigma?BioXcel Therapeutics (NASDAQ:BTAI) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability. Which has more volatility and risk, BTAI or AIFC? BioXcel Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Which has stronger valuation & earnings, BTAI or AIFC? BioXcel Therapeutics has higher earnings, but lower revenue than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$640K52.11-$69.90M-$5.75N/AALT5 Sigma$24.84M4.40-$344.51MN/AN/A Do insiders & institutionals hold more shares of BTAI or AIFC? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to BTAI or AIFC? In the previous week, BioXcel Therapeutics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 2 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of -0.07 beat BioXcel Therapeutics' score of -1.09 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer BTAI or AIFC? BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 918.52%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is BTAI or AIFC more profitable? ALT5 Sigma has a net margin of -1,386.90% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-11,078.53% N/A -201.53% ALT5 Sigma -1,386.90%-50.52%-45.05% SummaryBioXcel Therapeutics beats ALT5 Sigma on 9 of the 14 factors compared between the two stocks.How does BioXcel Therapeutics compare to Coya Therapeutics?Coya Therapeutics (NASDAQ:COYA) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do insiders & institutionals have more ownership in COYA or BTAI? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate COYA or BTAI? Coya Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 250.11%. BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 918.52%. Given BioXcel Therapeutics' higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk and volatility, COYA or BTAI? Coya Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Does the media refer more to COYA or BTAI? In the previous week, Coya Therapeutics had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 7 mentions for Coya Therapeutics and 3 mentions for BioXcel Therapeutics. Coya Therapeutics' average media sentiment score of 0.45 beat BioXcel Therapeutics' score of -1.09 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has preferable earnings and valuation, COYA or BTAI? Coya Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$7.95M13.49-$21.23M-$1.15N/ABioXcel Therapeutics$640K52.11-$69.90M-$5.75N/A Is COYA or BTAI more profitable? Coya Therapeutics has a net margin of -266.10% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya Therapeutics-266.10% -55.86% -48.86% BioXcel Therapeutics -11,078.53%N/A -201.53% SummaryCoya Therapeutics beats BioXcel Therapeutics on 12 of the 16 factors compared between the two stocks.How does BioXcel Therapeutics compare to Edesa Biotech?BioXcel Therapeutics (NASDAQ:BTAI) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Does the media favor BTAI or EDSA? In the previous week, Edesa Biotech had 7 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 10 mentions for Edesa Biotech and 3 mentions for BioXcel Therapeutics. Edesa Biotech's average media sentiment score of -0.42 beat BioXcel Therapeutics' score of -1.09 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Edesa Biotech 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in BTAI or EDSA? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate BTAI or EDSA? BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 918.52%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 58.16%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BTAI or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-11,078.53% N/A -201.53% Edesa Biotech N/A -286.52%-75.36% Which has more risk & volatility, BTAI or EDSA? BioXcel Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Which has preferable valuation and earnings, BTAI or EDSA? Edesa Biotech has lower revenue, but higher earnings than BioXcel Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$640K52.11-$69.90M-$5.75N/AEdesa BiotechN/AN/A-$7.19M-$1.34N/A SummaryEdesa Biotech beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks.How does BioXcel Therapeutics compare to Turn Therapeutics?Turn Therapeutics (NASDAQ:TTRX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Do institutionals & insiders have more ownership in TTRX or BTAI? 30.7% of BioXcel Therapeutics shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TTRX or BTAI more profitable? Turn Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets Turn TherapeuticsN/A N/A N/A BioXcel Therapeutics -11,078.53%N/A -201.53% Which has higher valuation & earnings, TTRX or BTAI? Turn Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurn TherapeuticsN/AN/A-$3.19M-$0.19N/ABioXcel Therapeutics$640K52.11-$69.90M-$5.75N/A Do analysts rate TTRX or BTAI? Turn Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 75.82%. BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 918.52%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Turn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer TTRX or BTAI? In the previous week, Turn Therapeutics had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 7 mentions for Turn Therapeutics and 3 mentions for BioXcel Therapeutics. Turn Therapeutics' average media sentiment score of 0.13 beat BioXcel Therapeutics' score of -1.09 indicating that Turn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative SummaryBioXcel Therapeutics beats Turn Therapeutics on 7 of the 13 factors compared between the two stocks.How does BioXcel Therapeutics compare to Kalaris Therapeutics?Kalaris Therapeutics (NASDAQ:KLRS) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Which has preferable earnings and valuation, KLRS or BTAI? Kalaris Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$43.44M-$2.15N/ABioXcel Therapeutics$640K52.11-$69.90M-$5.75N/A Does the media prefer KLRS or BTAI? In the previous week, Kalaris Therapeutics had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 3 mentions for BioXcel Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.38 beat BioXcel Therapeutics' score of -1.09 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has more volatility and risk, KLRS or BTAI? Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Is KLRS or BTAI more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -72.78% -43.49% BioXcel Therapeutics -11,078.53%N/A -201.53% Do institutionals and insiders have more ownership in KLRS or BTAI? 66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate KLRS or BTAI? Kalaris Therapeutics currently has a consensus price target of $15.60, suggesting a potential upside of 231.84%. BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 918.52%. Given BioXcel Therapeutics' higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryKalaris Therapeutics beats BioXcel Therapeutics on 11 of the 16 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition ExportMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.89M$3.25B$6.24B$12.23BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-0.1918.5220.7825.05Price / Sales52.11270.32531.2172.66Price / CashN/A124.5843.0954.25Price / Book-0.326.609.816.83Net Income-$69.90M$24.18M$3.55B$335.69M7 Day Performance-9.24%-3.74%-2.11%-2.15%1 Month Performance-10.00%-7.95%-4.14%-2.47%1 Year Performance-23.94%50.32%28.35%27.13% BioXcel Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics1.8056 of 5 stars$1.08-4.4%$11.00+918.5%-25.0%$34.89M$640KN/A90Negative NewsEarnings ReportAIFCALT5 Sigma0.1728 of 5 stars$0.97-6.1%N/A-87.4%$123.01M$24.84MN/A170Earnings ReportCOYACoya Therapeutics2.7706 of 5 stars$5.07-3.7%$16.00+215.9%-23.5%$118.83M$7.95MN/A6EDSAEdesa Biotech1.4981 of 5 stars$13.21-9.6%$5.00-62.1%+494.5%$117.80MN/AN/A20News CoverageEarnings ReportShort Interest IncreaseGap UpTTRXTurn Therapeutics2.8901 of 5 stars$3.94-2.1%$8.00+103.3%N/A$117.22MN/AN/A2News CoveragePositive NewsGap Down Related Companies and Tools Related Companies ALT5 Sigma Alternatives Coya Therapeutics Alternatives Edesa Biotech Alternatives Turn Therapeutics Alternatives Kalaris Therapeutics Alternatives Cardiff Oncology Alternatives Verrica Pharmaceuticals Alternatives NRx Pharmaceuticals Alternatives enGene Alternatives PepGen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
